Stockholm, Sweden — Medivir AB (OMX: MVIR) today announced a non-exclusive
collaboration between Janssen Pharmaceuticals Inc. (Janssen) and Idenix
Pharmaceuticals for the clinical development of an all-oral (interferon-free)
direct-acting antiviral (DAA) hepatitis C (HCV) combination therapy. The
collaboration will evaluate combinations including simeprevir (TMC435), a once
-daily protease inhibitor jointly developed by Janssen R&D Ireland and Medivir,
TMC647055, a potent once-daily NNI (non-nucleoside inhibitor) of the HCV
polymerase, boosted with low dose ritonavir, being developed by Janssen and
IDX719, Idenix’s once-daily pan-genotypic NS5A inhibitor.
